BT Share Offer: Why now?
Westpac is selling some of its shares in BT Investment Management. But is a great deal for the bank a good deal for you?
Virtus, Monash and the $30,000 babies
Forget Primary Health Care, the real risk to these IVF providers is the Government.
iCar Asia's capital raising
The share price has fallen but the reason makes sense. iCar Asia is raising sufficient capital to see it through to breakeven (or so management hopes).
The return of Caltex
Caltex's share price has slumped 18% from its highs. Is there value here once again?
Fairfax's prime real estate
Fairfax Media's Domain business is growing in leaps and bounds. So why does it get so little attention in the annual report?
Flight Centre loses altitude
Flight Centre's recent profit downgrade has investors worried. Is online competition finally hitting home?
Hansen's Pay TV payday
Netflix may be nipping at the Pay TV industry's heels, but it's still a booming business for Hansen.
ASX still offers good value
Despite uncertainty over the future of its equities clearing monopoly, the ASX still offers good value.
Clearing uncertainty dogs ASX
The pending decision on ASX's equities clearing monopoly has put pressure on its share price, but the market operator has a few cards up its sleeve.
Media storm hits IOOF
A series of serious allegations against IOOF Holdings in Fairfax newspapers have smashed the wealth manager's share price.
PMP: Back from the brink
After a decade facing a financial abyss, PMP is on a surer footing - and its share price has risen sharply. Gaurav Sodhi assesses whether any value remains.
Crunch time for Woolworths
The Woolworths ship is changing skippers. But whoever steers her, the course must be the same - margins need to come down.
Nanosonics' dirty little secret
Nanosonics is cleaning up in more ways than one, but its latest study adds little value.
iCar Asia: Q2 update
The Asian online car classifieds business has provided an underwhelming second-quarter update, but it's better than it looks.
James Hardie's hidden appeal
Asbestos liabilities and cyclical markets aren't usually associated with a promising investment. But James Hardie is a much better business than it first appears.
James Hardie's stronger foundation
With asbestos liabilities looking under control, James Hardie is set to benefit from the continuing US housing recovery.
STW doesn't ad up
This marketing company is changing strategy but argues that dividend cuts and capital raisings are off the table. Jon Mills investigates.
Time to sell Fisher & Paykel Healthcare
F&P Healthcare is a good business but the current share price is just too high.
Fisher & Paykel Healthcare: Result 2015
F&P Healthcare has produced another sound result, but don't confuse a good company with a good investment.
South32 upgraded to Buy
With a volatile share price since listing, Gaurav Sodhi explains why South32 is a Buy.
SomnoMed sets new targets
With growing acceptance in Europe, SomnoMed's sales growth continues to impress. But don't expect free cash flow any time soon.
MG Unit Trust: the poor man's Murray Goulburn?
The MG Unit Trust will let you share in the performance of Murray Goulburn. But it's dairy farmers who will call the shots.
Correction: Soul Pattinson
We made two mistakes in our last Soul Patts update. Fortunately, they largely offset each other.
Medibank's slippery slope
Australia's largest private health insurer faces plenty of headwinds, but it's also better value.
Ainsworth warns on sales
Despite now forecasting a 2% fall in revenue, Ainsworth expects 2015 profit to be similar to 2014.
Call 1300 880 160
Start a chat
Schedule a call
